JP5166441B2 - 癌治療用イミダゾリジノニルアミノピリミジン化合物 - Google Patents

癌治療用イミダゾリジノニルアミノピリミジン化合物 Download PDF

Info

Publication number
JP5166441B2
JP5166441B2 JP2009543061A JP2009543061A JP5166441B2 JP 5166441 B2 JP5166441 B2 JP 5166441B2 JP 2009543061 A JP2009543061 A JP 2009543061A JP 2009543061 A JP2009543061 A JP 2009543061A JP 5166441 B2 JP5166441 B2 JP 5166441B2
Authority
JP
Japan
Prior art keywords
cancer
group
mmol
hydrogen
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009543061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513552A (ja
JP2010513552A5 (cg-RX-API-DMAC10.html
Inventor
リ・ホン−ユ
ハロルド・バーンズ・ブルックス
ジョイス・ゼット・クリッチ
ジェイムズ・ロバート・ヘンリー
メリッサ・ケイト・スレイター
ワン・ヤン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2010513552A publication Critical patent/JP2010513552A/ja
Publication of JP2010513552A5 publication Critical patent/JP2010513552A5/ja
Application granted granted Critical
Publication of JP5166441B2 publication Critical patent/JP5166441B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009543061A 2006-12-21 2007-12-11 癌治療用イミダゾリジノニルアミノピリミジン化合物 Expired - Fee Related JP5166441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87130206P 2006-12-21 2006-12-21
US60/871,302 2006-12-21
PCT/US2007/087044 WO2008076704A1 (en) 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Publications (3)

Publication Number Publication Date
JP2010513552A JP2010513552A (ja) 2010-04-30
JP2010513552A5 JP2010513552A5 (cg-RX-API-DMAC10.html) 2011-01-27
JP5166441B2 true JP5166441B2 (ja) 2013-03-21

Family

ID=39186811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543061A Expired - Fee Related JP5166441B2 (ja) 2006-12-21 2007-12-11 癌治療用イミダゾリジノニルアミノピリミジン化合物

Country Status (14)

Country Link
US (1) US8101628B2 (cg-RX-API-DMAC10.html)
EP (1) EP2125793B1 (cg-RX-API-DMAC10.html)
JP (1) JP5166441B2 (cg-RX-API-DMAC10.html)
KR (1) KR101088291B1 (cg-RX-API-DMAC10.html)
CN (1) CN101563342B (cg-RX-API-DMAC10.html)
AT (1) ATE479680T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007334039B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0721045A2 (cg-RX-API-DMAC10.html)
CA (1) CA2671738A1 (cg-RX-API-DMAC10.html)
DE (1) DE602007008952D1 (cg-RX-API-DMAC10.html)
EA (1) EA016177B1 (cg-RX-API-DMAC10.html)
ES (1) ES2349169T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009006634A (cg-RX-API-DMAC10.html)
WO (1) WO2008076704A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2125794T1 (sl) 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
EA016781B1 (ru) * 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
WO2008144222A2 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP2007533602A (ja) * 2003-07-31 2007-11-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾチオフェン化合物及びそれらの使用
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
SI2125794T1 (sl) 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
EA016781B1 (ru) 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
WO2008144222A2 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds

Also Published As

Publication number Publication date
MX2009006634A (es) 2009-06-30
EA016177B1 (ru) 2012-02-28
KR101088291B1 (ko) 2011-11-30
AU2007334039A1 (en) 2008-06-26
BRPI0721045A2 (pt) 2014-07-29
US20100076001A1 (en) 2010-03-25
WO2008076704A1 (en) 2008-06-26
ES2349169T3 (es) 2010-12-28
KR20090086114A (ko) 2009-08-10
EA200970615A1 (ru) 2009-10-30
CN101563342A (zh) 2009-10-21
ATE479680T1 (de) 2010-09-15
US8101628B2 (en) 2012-01-24
JP2010513552A (ja) 2010-04-30
EP2125793B1 (en) 2010-09-01
CA2671738A1 (en) 2008-06-26
EP2125793A1 (en) 2009-12-02
CN101563342B (zh) 2012-09-05
AU2007334039B2 (en) 2012-02-16
DE602007008952D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
JP5248600B2 (ja) トリアゾリルアミノピリミジン化合物
US20100130496A1 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
KR101080594B1 (ko) 암의 치료를 위한 이미다졸리디노닐 아미노피리미딘 화합물
JP5204838B2 (ja) トリアゾリルアミノピリミジン化合物
KR101088291B1 (ko) 암의 치료를 위한 이미다졸리디노닐 아미노피리미딘 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121220

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees